Loading…
PRISM0CAL is a brand name for Magnesium Chloride, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Adverse Drug Reaction Overview Adverse drug reactions can result from the solution used or the treatment. Bicarbonate-buffered hemofiltration and hemodialysis solutions are generally well tolerated.
However, the following adverse drug reactions are conceivable:
Hyper- or hypovolemia, electrolyte disturbances, hypophosphataemia, metabolic alkalosis. Some adverse reactions related to the dialysis treatments (hemodialysis, hemofiltration and hemodiafiltration) can occur, such as nausea, vomiting, and muscle cramps.
Other adverse reactions reported with similar products include • Hypotension • Acid–base balance disorders • Electrolyte imbalance • Fluid imbalance Clinical Trial Adverse Drug Reactions Not applicable Less Common Clinical Trial Adverse Drug Reactions (<1%) Not applicable Abnormal Hematologic and Clinical Chemistry Findings Not applicable Post-Market Adverse Drug Reactions No serious and/or unexpected adverse drug reactions, other than those listed in the previous ADVERSE REACTIONS subsections, have been reported post market.
DRUG INTERACTIONS Overview The blood concentration of filterable/dialysable drugs may be reduced during treatment due to their removal by the extracorporeal filter. Corresponding corrective therapy should be instituted if necessary to establish the desired blood concentrations for drugs removed during treatment.
Interactions with other medications can be avoided by correct dosage of the solution for hemofiltration and hemodialysis and precise monitoring. It is the responsibility of the physician to consider the compatibility of any medication that is to be mixed with the Prism0CAL solution, by checking for colour change and precipitation of insoluble complexes or crystals.
The Instructions for Use of the medication to be added must be consulted. Prism0CAL Page 7 of 19 The compatible medication must be added to the reconstituted solution and the solution must be administered immediately. Medication should only be added under the direction of a physician in the following way: Remove any fluid from injection port, hold the bag upside down, insert the drug through the injection port and mix thoroughly.
When introducing additives, use aseptic techniques. The solution must be administered immediately. Drug-Drug Interactions Interactions with other drugs have not been established. However, the following interactions are conceivable: • The risk of digitalis-induced cardiac arrhythmia is increased during hypokalaemia; • Additional sodium bicarbonate [or buffer source] contained in the CRRT fluids or in other fluids administered during therapy may increase the risk of metabolic alkalosis.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Magnesium Chloride in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
• When citrate is used as an anticoagulant, it contributes to the overall buffer load and can reduce plasma calcium levels. Drug-Food Interactions Interactions with food have not been established. Drug-Herb Interactions Interactions with herbal products have not been established.
Drug-Laboratory Interactions Interactions with laboratory tests have not been established. Drug-Lifestyle Interactions Not relevant DOSAGE AND ADMINISTRATION Dosing Considerations The rate at which Prism0CAL is administered depends on the blood concentration of electrolytes, acid-base balance, fluid balance and overall clinical condition of the patient.
The volume of replacement solution and/or dialysate to be administered will also depend on the desired intensity (dose) of the treatment. The solution should be prescribed and administration (dose, infusion rate and cumulative volume) should be established only by a physician experienced in critical care medicine and CRRT.
2 mmol/L may be added to Prism0CAL. If potassium phosphate is added, the total potassium concentration should not exceed 4 mEq/L (4 mmol/L). 73 m2 Commonly used flow rates in adults are approximately 2000 to 2500 mL/h which correspond to a daily fluid volume of approximately 48 to 60 L.
Prism0CAL has an osmolarity of 282 mOsmol/L. Missed Dose Not relevant, since Prism0CAL is administered continuously. Administration Intravenous use for hemofiltration (and part of hemodiafiltration) and dialysis transmembrane use for hemodialysis.
Prism0CAL is used as a replacement solution and/or dialysate. Prism0CAL, when used as replacement solution, is administered into the extra-corporeal circuit before (pre-dilution) or after (post-dilution) the hemofilter or hemodiafilter.
Prism0CAL, when used as a dialysis fluid (dialysate), is administered in the dialysate compartment of the filter separated from the blood flow by a semipermeable membrane. Use only with appropriate extracorporeal renal replacement equipment.
6 °F) to enhance patient comfort. , heating pad, warming plate). Solutions should not be heated in water or in a microwave oven due to the potential for patient injury or discomfort. Prism0CAL should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Do not administer unless the solution is clear and the seal is intact.
Reconstitution:
The solution in the small compartment A is added to the solution in the large compartment B after breaking the peel seal immediately before use to obtain the clear and colorless reconstituted solution.
INSTRUCTION FOR USE:
Aseptic technique should be used throughout the handling […]